Azilsartan medoxomil plus chlorthalidone is superior to olmesartan plus hydrochlorothiazide for the treatment of stage 2 systolic hypertension, say researchers. In a triple-arm, double-blind study, Cushman et al. randomly allocated 1,071 participants to receive high-dose or low-dose azilsartan medoxomil plus chlorthalidone, or olmesartan medoxomil plus hydrochlorothiazide. Decreases in clinic and ambulatory systolic blood pressures were greater in both azilsartan medoxomil–chlorthalidone groups than in the olmesartan–hydrochlorothiazide group after 12 weeks.
ORIGINAL RESEARCH PAPER
Cushman, W. C. et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension doi:10.1161/HYPERTENSIONAHA.111.188284
Rights and permissions
About this article
Cite this article
Azilsartan medoxomil for stage 2 systolic hypertension. Nat Rev Nephrol 8, 435 (2012). https://doi.org/10.1038/nrneph.2012.133
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.133
